Oppenheimer has recently reiterated Keros Therapeutics Inc (KROS) stock to Outperform rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 16, 2024, Guggenheim had ...

Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from ...

Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to ...

Oppenheimer analyst Andreas Argyrides reiterated a Buy rating on Keros Therapeutics (KROS – Research Report) yesterday and set a price target ...

In a report released today, Srikripa Devarakonda from Truist Financial assigned a Buy rating to Keros Therapeutics (KROS – Research Report). The company’s shares closed yesterday at $10.42. Discover ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

The action affects the TROPOS trial of cibotacept (KER-012), an activin signalling inhibitor that works in a similar way to ...

Taken together with Keros’ recent pivot away from obesity, the termination of its pulmonary arterial hypertension study could ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) have been assigned a consensus recommendation of “Moderate ...